Index to volume 16 (no. 1-12) (2013) for health professionals who care for cancer patients

| VOLUME 16                           | Janua    | ry-December        | 2013      |
|-------------------------------------|----------|--------------------|-----------|
| No. 1<br>No. 2<br>No. 3supplement 1 | February | No. 9              | September |
| No. 4                               | April    | No. 11supplement 1 | November  |
| No. 5                               | ,        |                    | December  |

# SUBJECT INDEX

Α

# **Ambiguous Medical Notations**

Medication Safety Corner - Safe Practices Around, vol 16 (3)

# **Asparaginase**

Cancer Drug Manual – revised, vol 16 (6)

#### Azacitidine

Cancer Drug Manual – revised, vol 16 (2)

В

## **BCCA Conference**

Continuing Professional Development – BCCA Conference 2013 Cancelled, vol 16 (8)

## **BCCA DERS Pump Library**

<u>Medication Safety Corner</u> – BCCA DERS Pump Library – Reduction in Air Sensitivity Detection Settings, vol 16 (12)

#### **BCCA Education**

<u>Continuing Professional Development</u> – BCCA Education Program for Oncology Pharmacists – Now available via Learning Hub, vol 16 (8); BCCA Education Program for Oncology Pharmacists – New Modules Available, vol 16 (12)

#### **Bendamustine**

<u>Benefit Drug List</u> – new: and Rituximab for Indolent Non-Hodgkin Lymphoma and Mantle Cell Lymphoma, vol 16 (6)

Cancer Drug Manual - new, vol 16 (5)

<u>Editor's Choice</u> – new program: for Relapsed Chronic Lymphocytic Leukemia, vol 16 (2); new program: and Rituximab for Indolent Non-Hodgkin Lymphoma and Mantle Cell Lymphoma, vol 16 (6)

Benefit Drug List – new: for Relapsed Chronic Lymphocytic Leukemia, vol 16 (2)

## Bevacizumab

Cancer Drug Manual - revised, vol 16 (8)

## **BMTLPDRIT**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (9)

#### **Bortezomib**

<u>Drug Update</u> – Fatal Bortezomib Intrathecal Administration, vol 16 (2) <u>Cancer Drug Manual</u> – revised, vol 16 (12)

#### **BRAJACT**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (10)

BRAJACTG

List of New and Revised Protocols, PPOs and Patient Handouts – revised, vol 16 (10)

## **BRAJACTT**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (10)

#### **BRAJACTTG**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (10)

#### **UBRAJACTW**

Benefit Drug List – revised, vol 16 (9)

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (1); revised, vol 16 (5); revised, vol 16 (9)

### **BRAJANAS**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (10)

## **UBRAJCAF**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – deleted, vol 16 (2)

## **BRAJCAFG**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5)

#### **BRAJCAFPO**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5); Precautions Updated in Patient Handouts on Cardiac Toxicities Associated with Fluorouracil and Capecitabine, vol 16 (9)

#### **UBRAJCEF**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – deleted, vol 16 (2)

## BRAJCEFG

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5)

## **BRAJCMF**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5);

Precautions Updated in Patient Handouts on Cardiac Toxicities Associated with Fluorouracil and Capecitabine, vol 16 (9)

#### **BRAJCMFPO**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5); Precautions Updated in Patient Handouts on Cardiac Toxicities Associated with Fluorouracil and Capecitabine, vol 16 (9)

#### **BRAJDCARBT**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6)

## **BRAJDTFEC**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5); Precautions Updated in Patient Handouts on Cardiac Toxicities Associated with Fluorouracil and Capecitabine, vol 16 (9)

#### **BRAJEXE**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (10)

## **BRAJFEC**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5); Precautions Updated in Patient Handouts on Cardiac Toxicities Associated with Fluorouracil and Capecitabine, vol 16 (9)

## **BRAJFECD**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5); Precautions Updated in Patient Handouts on Cardiac Toxicities Associated with Fluorouracil and Capecitabine, vol 16 (9)

#### **BRAJFECDT**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (2); Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5); revised, vol 16 (10)

#### **BRAJLET**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (2); revised, vol 16 (7); revised, vol 16 (10)

#### **BRAJTAM**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (6); revised, vol 16 (7); revised, vol 16 (10); revised, vol 16 (12)

## **BRAJTDC**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (1)

## **BRAVCAF**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5);

Precautions Updated in Patient Handouts on Cardiac Toxicities Associated with Fluorouracil and Capecitabine, vol 16 (9)

#### **BRAVCAP**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5)

## **BRAVCMF**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5); Precautions Updated in Patient Handouts on Cardiac Toxicities Associated with Fluorouracil and Capecitabine, vol 16 (9)

#### **BRAVCMFPO**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5)

#### **BRAVDCAP**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5)

#### **BRAVEVEX**

Benefit Drug List – new, vol 16 (12)

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – new, vol 16 (12)

#### **BRAVEXE**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (12)

#### **BRAVGEMP**

List of New and Revised Protocols, PPOs and Patient Handouts – revised, vol 16 (8)

#### **UBRAVLCAP**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (2); Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5)

#### **UBRAVPTRAD**

Benefit Drug List – new, vol 16 (11)

List of New and Revised Protocols, PPOs and Patient Handouts – new, vol 16 (11)

#### **UBRAVTCAP**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (2); Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5)

#### **BRAVTPCARB**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (4); Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6)

## **BRAVTRVIN**

List of New and Revised Protocols, PPOs and Patient Handouts – revised, vol 16 (1)

## **Brentuximab**

Cancer Drug Manual – revised, vol 16 (6)

## **BRINFCAF**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5)

#### **BRINFCEF**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (2); Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5); Precautions Updated in Patient Handouts on Cardiac Toxicities Associated with Fluorouracil and Capecitabine, vol 16 (9)

#### BRINFCEFG

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5)

#### **UBRLA2**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5)

#### **BRLAACDT**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (10)

## **UBRLAACTW**

Benefit Drug List – new, vol 16 (4); revised, vol 16 (9)

List of New and Revised Protocols, PPOs and Patient Handouts – new, vol 16 (4)

## **UBRLACEF**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5); Precautions Updated in Patient Handouts on Cardiac Toxicities Associated with Fluorouracil and Capecitabine, vol 16 (9)

#### **UBRLACEFG**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5)

C

#### Cabazitaxel

<u>Editor's Choice</u> – new program: Genitourinary-Cabazataxel with Prednisone for Metastatic Resistant Prostate Cancer After Progression on Docetaxel, vol 16 (8)

# Canadian Association of Nurses in Oncology (CANO)

Continuing Professional Development - CANO Conference 2013, vol 16 (8)

# **Canadian Breast Cancer Symposium 2014**

Continuing Professional Development, vol 16 (12)

#### Capecitabine

Cancer Drug Manual - revised, vol 16 (9)

## Carboplatin

<u>Cancer Drug Manual</u> – Translation of Patient Information, vol 16 (12)

Drug Update - Change in Carboplatin Diluent Solution to Normal Saline, vol 16 (6)

## Cardiotoxicity

<u>Editor's Choice</u> – Highlights of Changes in Protocols, Pre-Printed Orders and Patient Handouts: Cardiotoxicity Associated with Fluoropyrimidines, vol 16 (9)

## Cetuximab

<u>Cancer Drug Manual – revised, vol 16 (5); Translation of Patient Information, vol 16 (12)</u>

## Chlorambucil

<u>Cancer Drug Manual</u> – Translation of Patient Information, vol 16 (12)

## **CISplatin**

<u>Cancer Drug Manual</u> – Translation of Patient Information, vol 16 (12)

Editor's Choice – new programs: with Capecitabine and Radiation for Adjuvant Resected Gastric Cancer, vol 16 (3); new program: Head and Neck – Cisplatin and Docetaxel in Squamous Cell Carcinoma of Head and Neck, vol 16 (8)

#### CML

<u>Editor's Choice</u> – Highlights of Changes in Protocols, Pre-Printed Orders and Patient Handouts: Eligibility Criteria for CML Protocols Revised to Reflect Updated Guidelines, vol 16 (11)

# **CNAJTZRT**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (1); revised, vol 16 (9)

### **CNB**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (8)

## **UCNBEV**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (2); revised, vol 16 (10)

#### **CNCAB**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (8)

#### **CNCARV**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6)

#### CNQUIN

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (8)

#### **CNTAMCAR**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6)

#### **CNTEMOZ**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (9)

## **UCNTEMOZMD**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (2)

## Compassionate Access Program (CAP)

Compassionate Access Program - Pearls for CAP Users, vol 16 (9)

<u>Provincial Systemic Therapy Policy</u> – Updates to BCCA Compassionate Access Program (CAP) Policy, vol 16 (7)

## CON

<u>Communities Oncology Network</u> – CON Site Contact Information, vol 16 (1) <u>Editor's Choice</u> – CON Protocol Codes on All Claims, vol 16 (4); CON Protocol Code Project – Results of Second Audit, vol 16 (4)

# Cyclophosphamide

<u>Benefit Drug List</u> – deleted – and Fluorouracil with DOXOrubicin or Epirubicin for Adjuvant Breast Cancer, vol 16 (2)

D

# **Degarelix**

Cancer Drug Manual – revised, vol 16 (8)

#### Dexamethasone

Benefit Drug List – revised: Dexamethasone and CISplatin for Lyphoma, vol 16 (1)

#### Dexraxozane

Cancer Drug Manual – revised, vol 16 (1)

#### **DOCEtaxel**

Cancer Drug Manual - revised, vol 16 (4)

<u>Drug Update</u> – Associated Lung Toxicity, vol 16 (2)

#### Doxorubicin

Cancer Drug Manual – Translation of Patient Information, vol 16 (12)

Ε

## **Editorial Board Membership**

Cancer Drug Manual - vol 16 (6)

Systemic Therapy Update Editorial Board – vol 16 (12)

#### Elasomeric

Medication Safety Corner – Elastomeric INFUSOR® Rate, vol 16 (12)

#### **Endocrine**

Editor's Choice – Adjuvant Therapy for Early Breast Cancer, vol 16 (7)

## **Enzalutamide**

Cancer Drug Manual – new, vol 16 (12)

<u>Editor's Choice</u> – new programs: Enzalutamide for Metastatic Castration Resistant Prostate Cancer (UGUPENZ), vol 16 (12)

## **Erythropoiesis**

<u>Editor's Choice</u> – Highlights of Changes in Protocols, PPOs and Patient Handouts, Updating Guidelines for Use of Erythropoiesis-Stimulating Agents, vol 16 (2)

# **Everolimus**

<u>Editor's Choice</u> – new programs: Everolimus with Exemestane for Advanced Breast Cancer (BRAVEVEX), vol 16 (12)

F

# **Family Practice Oncology**

<u>Continuing Professional Development</u> – Family Practice Oncology CMD Day 2013, vol 16 (10)

## **Fluorouracil**

Editor's Choice - Cardiotoxicity Associated with Fluorouracil and Capecitabine, vol 16 (5)

G

#### Gemcitabine

Benefit Drug List – revised: Gemcitabine with CISplatin for Adjuvant Urothelial Carcinoma, vol 16 (1)

<u>Cancer Drug Manual</u> – revised, vol 16 (8); Translation of Patient Information, vol 16 (12)

#### **GIAJCAP**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5)

#### **GIAJCAPOX**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5); Removal of Calcium Gluconate and Magnesium Sulfate from all Oxaliplatin-Containing Chemotherapy Protocols and PPPOs, vol 16 (7); Precautions Updated in Patient Handouts on Cardiac Toxicities Associated with Fluorouracil and Capecitabine, vol 16 (9)

#### **GIAJFFOX**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5); revised, vol 16 (7); Removal of Calcium Gluconate and Magnesium Sulfate from all Oxaliplatin-Containing Chemotherapy Protocols and PPPOs, vol 16 (7)

#### **GIAJFL**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5); revised, vol 16 (11)

#### **GIAVCAP**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5)

## **GIAVCETIR**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (7); Diuretic Drug Interaction Removed from Irinotecan-Containing Patient Handouts, vol 16 (7); revised, vol 16 (9)

## GIAVFL

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5); revised, vol 16 (11)

#### **GIAVTZCAP**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5); Precautions Updated in Patient Handouts on Cardiac Toxicities Associated with Fluorouracil and Capecitabine, vol 16 (9)

## **UGICAPIRI**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5); Diuretic Drug Interaction Removed from Irinotecan-Containing Patient Handouts, vol 16 (7); Precautions Updated in Patient Handouts on Cardiac Toxicities Associated with Fluorouracil and Capecitabine, vol 16 (9)

#### **UGICAPOX**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5); Removal of Calcium Gluconate and Magnesium Sulfate from all Oxaliplatin-Containing Chemotherapy Protocols and PPPOs, vol 16 (7); Precautions Updated in Patient Handouts on Cardiac Toxicities Associated with Fluorouracil and Capecitabine, vol 16 (9)

#### **GICART**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (1); Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5); Precautions Updated in Patient Handouts on Cardiac Toxicities Associated with Fluorouracil and Capecitabine, vol 16 (9); revised, vol 16 (11)

#### **UGICIRB**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5); Diuretic Drug Interaction Removed from Irinotecan-Containing Patient Handouts, vol 16 (7); Precautions Updated in Patient Handouts on Cardiac Toxicities Associated with Fluorouracil and Capecitabine, vol 16 (9)

## **UGICOXB**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5); Removal of Calcium Gluconate and Magnesium Sulfate from all Oxaliplatin-Containing Chemotherapy Protocols and PPPOs, vol 16 (7); Precautions Updated in Patient Handouts on Cardiac Toxicities Associated with Fluorouracil and Capecitabine, vol 16 (9)

#### **GICPART**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (1); Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5); Precautions Updated in Patient Handouts on Cardiac Toxicities Associated with Fluorouracil and Capecitabine, vol 16 (9)

#### **UGIEFUPRT**

List of New and Revised Protocols, PPOs and Patient Handouts – revised, vol 16 (5)

#### **UGIENACTRT**

Benefit Drug List – revised, vol 16 (3)

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (1); revised, vol 16 (3); revised, vol 16 (5); revised, vol 16 (6); Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6); revised, vol 16 (10)</u>

# **GIENAFUPRT**

Benefit Drug List – deleted, vol 16 (3)

List of New and Revised Protocols, PPOs and Patient Handouts – deleted, vol 16 (3)

## **GIFFIRB**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (2); revised, vol 16 (7); Diuretic Drug Interaction Removed from Irinotecan-Containing Patient Handouts, vol 16 (7); revised, vol 16 (10)

#### **UGIFFOXB**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (2); revised, vol 16 (7); Removal of Calcium Gluconate and Magnesium Sulfate from all Oxaliplatin-Containing Chemotherapy Protocols and PPPOs, vol 16 (7)

## **UGIFIRINOX**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5); Removal of Calcium Gluconate and Magnesium Sulfate from all Oxaliplatin-Containing Chemotherapy Protocols and PPPOs, vol 16 (7); Diuretic Drug Interaction Removed from Irinotecan-Containing Patient Handouts, vol 16 (7); revised, vol 16 (12)

#### **GIFOLFIRI**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (2); revised, vol 16 (7); Diuretic Drug Interaction Removed from Irinotecan-Containing Patient Handouts, vol 16 (7)

#### **GIFOLFOX**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (2); revised, vol 16 (7); Removal of Calcium Gluconate and Magnesium Sulfate from all Oxaliplatin-Containing Chemotherapy Protocols and PPPOs, vol 16 (7)

#### **GIFUART**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5)

#### **GIFUC**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (2)

#### **GIFUFA**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (5)

## **GIFUINF**

Benefit Drug List – deleted, vol 16 (11)

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (5); deleted, vol 16 (11)

#### **GIFUPART**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5)

#### **GIGAIRT**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5)

#### **UGIGAJCC**

Precautions Updated in Patient Handouts on Cardiac Toxicities Associated with Fluorouracil and Capecitabine, vol 16 (9)

## **UGIGAJCPRT**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5)

### **UGIGAVCCT**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5);

revised, vol, (8); Precautions Updated in Patient Handouts on Cardiac Toxicities Associated with Fluorouracil and Capecitabine, vol 16 (9); revised, vol 16 (10); revised, vol 16 (11)

## **UGIGAVCFT**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (1); Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5); revised, vol 16 (10)

### **UGIGAJCC**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (2)

#### **UGIGAJCPRT**

Benefit Drug List – new, vol 16 (3)

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – new, vol 16 (3); new, vol 16 (9)

#### **GIGAVECC**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5); Precautions Updated in Patient Handouts on Cardiac Toxicities Associated with Fluorouracil and Capecitabine, vol 16 (9)

#### **GIGAVECF**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5)

## **GIGECC**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5); Precautions Updated in Patient Handouts on Cardiac Toxicities Associated with Fluorouracil and Capecitabine, vol 16 (9)

#### **GIGECF**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5)

#### **GIGFOLFIRI**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (2); Diuretic Drug Interaction Removed from Irinotecan-Containing Patient Handouts, vol 16 (7)

## **GIHIPEC**

Benefit Drug List – new, vol 16 (10)

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – new, vol 16 (10); revised, vol 16 (12)

#### GIIR

Diuretic Drug Interaction Removed from Irinotecan-Containing Patient Handouts, vol 16 (7)

## **GIIRINALT**

Diuretic Drug Interaction Removed from Irinotecan-Containing Patient Handouts, vol 16 (7)

#### **GINPRRT**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – new, vol 16 (12)

## **GIPE**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (10)

#### **GIPGEM**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (1)

## **UGIPNEVER**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (12)

#### **GIRAJCOX**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5); revised, vol 16 (7); Removal of Calcium Gluconate and Magnesium Sulfate from all Oxaliplatin-Containing Chemotherapy Protocols and PPPOs, vol 16 (7); Precautions Updated in Patient Handouts on Cardiac Toxicities Associated with Fluorouracil and Capecitabine, vol 16 (9)

#### **GIRAJFFOX**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5); revised, vol 16 (7); Removal of Calcium Gluconate and Magnesium Sulfate from all Oxaliplatin-Containing Chemotherapy Protocols and PPPOs, vol 16 (7)

## **GIRCAP**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5)

#### **GIRCRT**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5)

## **GIRINFRT**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5)

#### **UGIYTT**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (5)

#### **GOBEP**

List of New and Revised Protocols, PPOs and Patient Handouts – revised, vol 16 (7)

#### **GOCXCAD**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6)

## **GOCXCAT**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6); revised, vol 16 (10)

## **GOCXCRT**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (1); revised, vol 16 (4)

#### GOENDCAD

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6)

#### GOENDCAT

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6); revised, vol 16 (7); revised, vol 16 (10)

#### GOENDH

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (1)

#### GOOVCADM

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6)

#### **GOOVCADR**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6)

## GOOVCADX

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6)

#### GOOVCAG

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (2); Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6)

#### **GOOVCARB**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6)

#### GOOVCATM

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6)

#### GOOVCATR

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6)

#### GOOVCATX

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (4); Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6)

## **UGOOVDDCAT**

Benefit Drug List – revised, vol 16 (9)

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (5); Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6); new, vol 16 (7); revised, vol 16 (7); revised, vol 16 (9); revised, vol 16 (10)</u>

#### GOOVETO

List of New and Revised Protocols, PPOs and Patient Handouts – revised, vol 16 (1)

#### GOOVGEM

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (4)

#### **GOOVIPPC**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (2); Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6); revised, vol 16 (10)

## GOOVLDOX

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (4); revised, vol 16 (7)

## **GOOVPLDC**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6); revised, vol 16 (7); revised, vol 16 (8)

#### **GOOVTAM**

Benefit Drug List – new, vol 16 (3)

List of New and Revised Protocols, PPOs and Patient Handouts – new, vol 16 (3)

#### GOOVTOP

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (4)

#### GOOVVIN

List of New and Revised Protocols, PPOs and Patient Handouts – revised, vol 16 (5)

#### GOSMCCRT

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6)

#### **UGOTDHR**

Benefit Drug List – revised, vol 16 (5)

List of New and Revised Protocols, PPOs and Patient Handouts – revised, vol 16 (5)

#### **GOTDLR**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (2)

#### **GUAJPG**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (1)

## **GUAVPG**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6); revised, vol 16 (11)

### **GUBCV**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6)

#### **GUBEP**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (3)

## **GUEP**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (3)

## **GUEVER**

Benefit Drug List – revised, vol 16 (12)

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (12)

#### **GUFUPRT**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5)

#### **UGUPABI**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (9); revised, vol 16 (12)

#### **UGUPAZO**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (10)

#### **UGUPCABA**

Benefit Drug List – new, vol 16 (8)

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – new, vol 16 (8); revised, vol 16 (12)

#### **UGUPENZ**

Benefit Drug List – new, vol 16 (12)

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – new, vol 16 (12)

## **GUPLHRHA**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (8)

#### **GUSCARB**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6)

#### GUSCPE

Benefit Drug List – new, vol 16 (8)

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – new, vol 16 (8)

#### **GUSCPERT**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6)

## Н

#### **HNAVDOC**

Benefit Drug List – revised, vol 16 (4)

List of New and Revised Protocols, PPOs and Patient Handouts – new, vol 16 (4)

#### **HNAVFUFA**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5)

#### **HNAVFUP**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5); Precautions Updated in Patient Handouts on Cardiac Toxicities Associated with Fluorouracil and Capecitabine, vol 16 (9); revised, vol 16 (10); revised, vol 16 (12)

## **HNAVPD**

Benefit Drug List – new, vol 16 (8)

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – new, revised, vol 16 (8); revised, vol 16 (10)

## **HNAVPE**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – new, vol 16 (10); revised, vol 16 (10)

#### **HNLACAFRT**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5); Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6)

## **UHNLADCF**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5); Precautions Updated in Patient Handouts on Cardiac Toxicities Associated with Fluorouracil and Capecitabine, vol 16 (9)

## **HNLAPRT**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (6)

#### **UHNNAVCAP**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5)

## **HNNAVFUFA**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5)

#### **HNNAVFUP**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5); Precautions Updated in Patient Handouts on Cardiac Toxicities Associated with Fluorouracil and Capecitabine, vol 16 (9); revised, vol 16 (10); revised, vol 16 (12)

# **HNNAVP**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (6)

#### **UHNNAVPC**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6)

#### **HNNAVPE**

SUBJECT INDEX List of New and Revised Protocols, PPOs and Patient Handouts – new, vol 16 (10); revised, vol 16 (10); new, vol 16 (12) **HNNAVPG** List of New and Revised Protocols, PPOs and Patient Handouts – new, vol 16 (6); revised, vol 16 (12) **HNNLAPRT** <u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (3) **HNOTTSH** <u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (7); revised, vol 16 (8); revised, vol 16 (12) **HNSAVFAC** <u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5) **HNSAVFUP** <u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Precautions on Cardiac Toxicities Associated with Fluorouracil and Capecitabine revised, vol 16 (5)

## **HNSAVNP**

List of New and Revised Protocols, PPOs and Patient Handouts – revised, vol 16 (5)

## **HNSAVPAC**

List of New and Revised Protocols, PPOs and Patient Handouts – revised, vol 16 (1)

## Hydroxyurea

Communities Oncology Network – Protocol Coding for, vol 16 (3)

# **Hyperthermic Intraperitoneal Chemotherapy**

Editor's Choice – new programs: Gastrointestinal: Hyperthermic Intraperitoneal Chemotherapy using Oxaliplatin and Fluorouracil for Peritoneal Carcinomatosis from Limited Advanced Colorectal and Appendiceal Carcinomas (GIHIPEC), vol 16 (10)

## **Imatinib**

Drug Update – dispensing, vol 16 (7)

Editor's Choice - Generic imatinib, vol 16 (10)

# **International Symposium on Oncology Pharmacy Practice (ISOPP)**

Continuing Professional Development – ISOPP 2014, vol 16 (11)

# **Ipilimumab**

Cancer Drug Manual – revised, vol 16 (1)

## Iriniotecan

Editor's Choice - new programs: with or without Platinum for Extensive Small Cell Lung Cancer, vol 16 (3)

# **Laboratory Tests**

Editor's Choice – Ordering by Pharmacists, Update on PSTP Policies, vol 16 (4) Letrozole

<u>Editor's Choice</u> – revised programs, 5 years Approved Following 5 years of Tamoxifen in Adjuvant Breast Cancer, vol 16 (2)

#### Leucovorin

Cancer Drug Manual – revised, vol 16 (4)

#### **LKCMLD**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (11)

#### **LKCMLI**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (10); revised, vol 16 (11)

#### **ULKCMLN**

List of New and Revised Protocols, PPOs and Patient Handouts – revised, vol 16 (11)

#### **ULKMDSA**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (7)

#### ULKMFRUX

Benefit Drug List – new, vol 16 (11)

List of New and Revised Protocols, PPOs and Patient Handouts - new, vol 16 (11)

# **Look-Alike Product Alert**

Medication Safety Corner – Phenylephrine vs diphenhydrAMINE, vol 16 (6)

#### **LUAJPC**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6)

#### **LUAVNP**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6)

#### **LUAVPC**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6)

#### LUAVPG

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6)

#### **LUAVPP**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6)

## **LULAPERT**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6)

## **LUMMPP**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6)

## LUOTPE

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6)

## **LUOTPERT**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6)

## LUPUPE

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6)

## **LUSCPE**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6)

#### **LUSCPERT**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6)

#### LUSCPI

Benefit Drug List - new, vol 16 (3)

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – new, vol 16 (3); Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6); revised, vol 16 (8)

#### LYABVD

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (6)

# ULYALEM

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (2)

#### **ULYBEND**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (8)

#### **ULYBENDR**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – new, vol 16 (6); revised, vol 16 (8); revised, vol 16 (11)

#### **LYCHOPR**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (9)

#### LYCODOXMR

List of New and Revised Protocols, PPOs and Patient Handouts – revised, vol 16 (9)

#### **ULYCLLBEND**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – new, vol 16 (2); revised, vol 16 (8)

#### LYCODOXMR

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (1)

#### **LYCVPR**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (9)

## **LYFLUDR**

List of New and Revised Protocols, PPOs and Patient Handouts – revised, vol 16 (8)

## LYGDP

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – new, vol 16 (2)

## **LYGDPR**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (9)

#### LYHDMRP

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (1); revised, vol 16 (2)

## **LYHDMTXP**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (1); revised vol 16 (2)

## **LYHDMTXR**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (1); revised vol 16 (2)

#### **LYIAVACR**

List of New and Revised Protocols, PPOs and Patient Handouts – revised, vol 16 (9)

#### ULYRICE

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6); revised, vol 16 (9)

#### **ULYRITUX**

List of New and Revised Protocols, PPOs and Patient Handouts – revised, vol 16 (8)

## **LYRITZ**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (9)

#### ULYRMTN

List of New and Revised Protocols, PPOs and Patient Handouts – revised, vol 16 (8)

#### Μ

#### Methotrexate

Cancer Drug Manual – revised, vol 16 (9)

<u>Editor's Choice</u> – Revised: Methotrexate Levels for initiating Oral Leucovorin in High-Dose Methotrexate Protocols, vol 16 (1)

#### Mitomycin (IV)

<u>Cancer Drug Manual</u> – Translation of Patient Information, vol 16 (12)

#### MODEXA

List of New and Revised Protocols, PPOs and Patient Handouts – new, vol 16 (4)

#### MOHDMTX

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (1)

#### **UMYMPT**

List of New and Revised Protocols, PPOs and Patient Handouts – revised, vol 16 (12)

Ν

# **National Oncology Pharmacy Symposium (NOPS)**

<u>Continuing Professional Development</u> – NOPS 2013, vol 16 (8); reminder NOPS 2013, vol 16 (9)

#### **Nilotinib**

Cancer Drug Manual - revised, vol 16 (6)

#### Nurses

<u>Nursing Update</u> – Supporting Continuing Competency for Chemotherapy Certified Nurses, vol 16 (4)

0

## **OSCAR**

Communities Oncology Network - Reminder Submission Deadline, vol 16 (3)

# Oxaliplatin

<u>Cancer Drug Manual</u> – revised, vol 16 (4)

<u>Editor's Choice</u> – Highlights of Changes in Protocols, PPOs and Patient Handouts: Removal of Calcium and Magnesium from all Oxaliplatin-Containing Chemotherapy Protocols and PPPOs, vol 16 (7)

Р

## **PACLitaxel**

Cancer Drug Manual – revised, vol 16 (4)

<u>Editor's Choice</u> – new program: Weekly PACLitaxel for Locally Advanced Breast Cancer, vol 16 (4)

## **Pazopanib**

<u>Cancer Drug Manual</u> – revised, vol 16 (10)

# Pegylated Liposomal DOXOrubicn (CAELYX®)

<u>Drug Update</u> – Drug Shortages Resolved, vol 16 (2); Update: Shortage of Pegylated Liposomal Doxorubicin (CAELYX®), vol 16 (11)

# **Pertuzumab**

<u>Cancer Drug Manual</u> – new: interim, vol 16 (8)

<u>Editor's Choice</u> – new programs: Pertuzumab with Trastuzumab and Docetaxel for Advanced Breast Cancer (UBRAVPTRAD), vol 16 (11)

## **Pharmacy Awareness Week**

Editor's Choice - vol 16 (3)

## **PHSA Learning Hub**

Communities Oncology Network - CON Access of, vol 16 (3)

## **Platinum**

<u>Editor's Choice</u> – new program: Platinum and Etoposide without Radiation for Genitourinary Small Cell Tumours, vol 16 (8)

#### **PUCAT**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – Change in CARBOplatin Diluent Solution and Reformatting Non-TALLman Lettering Drug Names to Lower Case, vol 16 (6); revised, vol 16 (11)

R

# **Radiation Therapy**

<u>Continuing Professional Development</u> – BCCA Radiation Therapy Education Series 2013, vol 16 (4)

## **RiTUXimab**

Beneift Drug List – revised: RiTUXimab with Gemcitabine, vol 16 (1)

<u>Drug Update</u> – Health Canada Advisory: Rituximab and Hepatitis B Virus Recreence, vol 16 (8)

<u>Editor's Choice</u> – Highlights of Changes in Protocols, Pre-Printed Orders and Patient Handouts: Revised Laboratory Monitoring in Rituximab-Containing Lymphoma Chemotherapy Protocols, vol 16 (9)

## Romidepsin

Cancer Drug Manual - new, vol 16 (11)

#### Ruxolitinib

<u>Cancer Drug Manual</u> – new, vol 16 (11)

<u>Editor's Choice</u> – new programs: Ruxolitinib for Symptomatic Myelofibrosis (ULKMFRUX), vol 16 (11)

S

## **SAAJAP**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (4)

## **SAVAC**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (11)

# **SAVVAP**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (4)

## **SAIME**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (2)

## **SCDEXA**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – deleted, vol 16 (4)

## **SCESA**

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (2)

#### USMAVIPI

<u>List of New and Revised Protocols, PPOs and Patient Handouts</u> – revised, vol 16 (1); revised, vol 16 (10)

## **USMAVVEM**

List of New and Revised Protocols, PPOs and Patient Handouts - revised, vol 16 (8)

# **Sunitinib**

<u>Cancer Drug Manual</u> – revised, vol 16 (12)

## **Symptom Management Guidelines**

Nursing Update - Updated BCCA Symptom Management Guidelines, vol 16 (10)

# **Systemic Therapy Treatments**

Editor's Choice - Update on PSTP Policies, vol 16 (4)

Т

# **TALLman Lettering**

<u>Drug Update</u> – Implementation Completed, vol 16 (4)

<u>Medication Safety Corner</u> – Implementation at the BCCA, vol 16 (3); Updates to BCCA Pharmacy Directive, vol 16 (7)

#### **Tamoxifen**

Cancer Drug Manual - revised, vol 16 (11)

Editor's Choice - new programs: for Advanced Ovarian Cancer, vol 16 (3); revised:

Extended Therapy in Adjuvant Breast Cancer, vol 16 (6)

#### Thalidomide

Cancer Drug Manual - revised, vol 16 (6); revised, vol 16 (8)

## Thioguanine

<u>Cancer Drug Manual</u> – Translation of Patient Information, vol 16 (12)

# Thyrotropin Alfa (THYROGEN®)

<u>Drug Update</u> – Drug Shortages Resolved, vol 16 (2); Shortage resolved, vol 16 (7)

## **Trastuzumab**

Cancer Drug Manual - revised, vol 16 (1)

Drug Update – Look-Alike/Sound-Alike Medication Alert, vol 16 (11)

<u>Medication Safety Corner</u> – Trastuzumab – Look-Alike/Sound-Alike Medication Alert, vol 16 (12)

## **Trastuzumab emtansine (T-DM1)**

Cancer Drug Manual – new, vol 16 (3)

W

# **Writing Team/Editorial Board Membership**

Cancer Drug Manual – revised, vol 16 (8)